1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > Nouriast (Parkinson’s Disease) - Forecast and Market Analysis to 2022

Nouriast (Parkinson’s Disease) - Forecast and Market Analysis to 2022

Summary

Parkinson’s disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, and postural instability. As the second most common neurodegenerative disorder, Parkinson’s disease may affect individuals of any age but prevalence is increased with age and it is most common in the elderly. Dopaminergic therapies have been fairly effective in treating bradykinesia, but several unmet needs remain. Some needs will be met during the forecast period from 2012-2022, while others, such as the need for disease-modifying drugs, will remain. GlobalData expects that advancements will be made in levodopa administration and that four new molecular entities will be introduced to the market by 2022, these factors along with increased patient numbers from an aging population will drive the market during the forecast period.

Istradefylline is a first-in-class adenosine A2 receptor inhibitor, marketed in Japan under the brand name Nouriast by Kyowa Hakko Kirin. It was approved in Japan for adjunct use with levodopa in advanced-stage patients with wearing-off in March 2013, and launched in May 2013 (Kyowa Hakko Kirin, press release, March 25, 2013; Kyowa Hakko Kirin, press release, May 29, 2013).

Scope

- Overview of Parkinson’s disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Nouriast including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Nouriast for the top seven countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Parkinson’s disease
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Nouriast performance
- Obtain sales forecast for Nouriast from 2012-2022 in the top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan).

Table Of Contents

Nouriast (Parkinson’s Disease) - Forecast and Market Analysis to 2022
1 Table of Contents

2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 8
3 Disease Overview 11
3.1 Etiology and Pathophysiology 11
3.1.1 Etiology 11
3.1.2 Pathophysiology 14
3.1.3 Prognosis 16
3.1.4 Quality of Life 17
3.2 Symptoms 17
4 Disease Management 19
4.1 Overview 19
4.1.1 Diagnosis - The UK Brain Bank Criteria 19
4.1.2 Treatment Guidelines and Leading Prescribed Drugs 20
4.2 Treatment Synopsis 23
4.2.1 Dopaminergic Therapy Classes 23
4.2.2 Treatment of Parkinson's Disease by Stage 25
4.2.3 Other Treatment Options 28
4.3 Parkinson's Disease Assessment Scales 28
4.3.1 Unified Parkinson's Disease Rating Scale (UPDRS) 29
4.3.2 Hoehn and Yahr Clinical Staging 31
4.3.3 Other Clinical Assessments 32
5 Competitive Assessment 33
5.1 Overview 33
5.2 Strategic Competitor Assessment 35
5.3 Product Profiles - Adenosine 2A Inhibitor 37
6 Nouriast (istradefylline) 38
6.1 Overview 38
6.2 Efficacy 39
6.3 Safety 40
6.4 SWOT Analysis 40
6.5 Forecast 41
7 Appendix 42
7.1 Bibliography 42
7.2 Abbreviations 46
7.3 Methodology 49
7.4 Forecasting Methodology 49
7.4.1 Diagnosed Parkinson's Disease Patients 49
7.4.2 Percent Drug-Treated Patients 50
7.4.3 General Pricing Assumptions 50
7.4.4 Compliance Assumptions 51
7.4.5 Individual Drug Assumptions 52
7.4.6 Generic Erosion 52
7.5 Physicians and Specialists Included in this Study 53
7.6 About the Authors 55
7.6.1 Author 55
7.6.2 Global Head of Healthcare 56
7.7 About GlobalData 57
7.8 Disclaimer 57

1.1 List of Tables

Table 1: Symptoms of Parkinson's Disease 18
Table 2: UK Brain Bank Diagnostic Criteria 20
Table 3: Diagnosis and Treatment Guidelines for Parkinson's Disease 21
Table 4: Most Prescribed Drugs for Parkinson's Disease by Class in the Global Markets, 2014 22
Table 5: Dopaminergic Therapy in Parkinson's Disease 25
Table 6: UPDRS Clinical Assessment of Disease Severity 30
Table 7: Parkinson's Disease Assessment Scales Used in Clinical Trials 32
Table 8: Treatment of Motor Symptoms in Parkinson's Disease 34
Table 9: Leading Treatments for Parkinson's Disease, 2014 36
Table 10: Product Profile - Nouriast 39
Table 11: Nouriast SWOT Analysis, 2014 40
Table 12: Global Sales Forecasts ($m) for Nouriast, 2012-2022 41

1.2 List of Figures

Figure 1: Overview - L-dopa Metabolism and Inhibitor Classes 24
Figure 2: Overview - Treatment of Motor Symptoms of Parkinson's Disease 26

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Parkinson%s Disease  - Market Insights, Epidemiology and Market Forecast-2023

Parkinson%s Disease  - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Parkinson’s Disease - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and ...

EpiCast Report: Schizophrenia - Epidemiology Forecast to 2025

EpiCast Report: Schizophrenia - Epidemiology Forecast to 2025

  • $ 3995
  • Industry report
  • November 2016
  • by Global Data

EpiCast Report: Schizophrenia - Epidemiology Forecast to 2025 Summary Schizophrenia is a severe mental disorder that affects an individual’s behaviors, thoughts, and emotions; it is extremely heterogeneous, ...

Parkinson%s Disease  - Epidemiology Forecast To 2023

Parkinson%s Disease  - Epidemiology Forecast To 2023

  • $ 2750
  • Industry report
  • January 2017
  • by Delve Insight

DelveInsight “Parkinson's Disease  - Epidemiology Forecast To 2023” provides an overview of the epidemiology trends of Parkinson's Disease  in seven major markets (US, France, Germany, Italy, Spain, ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.